Rorze

Rorze FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Rorze (6323.T) as of Oct 21, 2026 is 142.29 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 147.44 % — a change of -3.49% (lower).

FCF Conversion

142.29 %

YoY

-3.49%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Rorze is 2026 142.29 % . FCF Conversion Rate (FCF/EBITDA) of Rorze was 2025 147.44 % . It decreases by -3.49% lower compared to the previous year.

The Rorze FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
-135.48 JPY
Jan 1, 2020
10.54 JPY
Jan 1, 2021
88.27 JPY
Jan 1, 2022
7.01 JPY
Jan 1, 2023
-30.36 JPY
Jan 1, 2024
73.18 JPY
Jan 1, 2025
147.44 JPY
Jan 1, 2026
142.29 JPY
The Rorze FCF Conversion history
YEARFCF ConversionYoY
142.29 %-3.49%
147.44 %+101.47%
73.18 %-341.05%
-30.36 %-532.99%
7.01 %-92.06%
88.27 %+737.47%
10.54 %-107.78%
-135.48 %+97.26%
-68.68 %-181.74%
84.03 %+131.36%
36.32 %-60.24%
91.35 %+29.87%
70.34 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Rorze Stock analysis

What does Rorze do? Rorze Corp. generates revenue through the sale of automation systems for semiconductor and FPD production. The Semiconductor and FPD-related equipment segment offers products such as EFEM, wafer transporters for atmosphere and vacuum, wafer sorters, stockers for N2 purge, transport units, large glass substrate transporters, glass cutting machines, and stepping motor drivers and controllers. These products are sold to semiconductor and LCD industry clients. The Life Science segment provides cell culture devices including incubators, targeting the drug discovery industry and related fields. Both segments focus on delivering specialized equipment to industrial clients requiring precision manufacturing solutions in their respective markets. The company's primary customers in the semiconductor and FPD sectors are manufacturers of semiconductors and flat panel displays. These clients purchase automation systems to enhance production efficiency and maintain cleanroom standards. In the Life Science segment, pharmaceutical and biotechnology firms buy cell culture devices for research and development purposes. Rorze Corp. serves these segments with tailored equipment designed for high-precision industrial applications. Rorze Corp.'s business model revolves around developing and selling specialized machinery for two key industrial markets. The Semiconductor and FPD-related equipment segment drives the majority of sales with its range of dust-free transport solutions. The Life Science segment complements this by offering cell culture devices that support drug discovery processes. Both segments rely on direct sales to industrial clients seeking advanced automation for their manufacturing and research operations. Rorze is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Rorze stock

FCF Conversion Rate (FCF/EBITDA) of Rorze is 142.29 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Rorze changed from 147.44 % to 142.29 %, representing a -3.49% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Rorze since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Rorze with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Rorze

All Key Metrics — Rorze